Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript
Compared to Estimates, Evolent Health (EVH) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Evolent Health (EVH) Q4 Earnings Top Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.02 per share a year ago.
Is the Options Market Predicting a Spike in Evolent Health Stock?
Investors need to pay close attention to EVH stock based on the movements in the options market lately.
Evolent Health, Inc. (EVH) Presents at UBS Global Healthcare Conference 2025 Transcript
Evolent Health, Inc. ( EVH ) UBS Global Healthcare Conference 2025 November 11, 2025 5:00 PM EST Company Participants John Johnson - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Presentation Kevin Caliendo UBS Investment Bank, Research Division Good afternoon. This is Kevin Caliendo, health care service and distribution and IT analyst from UBS.
Evolent Health, Inc. (EVH) Q3 2025 Earnings Call Transcript
Evolent Health, Inc. ( EVH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Seth Blackley - Co-Founder, CEO & Director John Johnson - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Daniel Grosslight - Citigroup Inc., Research Division John Stansel - JPMorgan Chase & Co, Research Division Lucas Romanski - TD Cowen, Research Division Eduardo Ron - Truist Securities, Inc., Research Division Jeffrey Garro - Stephens Inc., Research Division Jessica Tassan - Piper Sandler & Co., Research Division David Larsen - BTIG, LLC, Research Division Matthew Shea - Needham & Company, LLC, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Presentation Operator Welcome to the Evolent Earnings Conference Call for the Third Quarter ended September 30, 2025. As a reminder, this conference call is being recorded.
Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CVS vs. EVH: Which Value-Based Care Stock Deserves Investor Attention?
CVS shows revenue growth and raised guidance, while EVH faces revenue declines but pursues oncology deals and efficiency gains.
Evolent Health, Inc. (EVH) Q2 2025 Earnings Call Transcript
Evolent Health, Inc. (NYSE:EVH ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants John Paul Johnson - Chief Financial Officer Seth Barrie Blackley - Co-Founder, CEO & Director Conference Call Participants Charles Rhyee - TD Cowen, Research Division Daniel R. Grosslight - Citigroup Inc., Research Division Eduardo Enrique Ron - Truist Securities, Inc., Research Division Jared Phillip Haase - William Blair & Company L.L.C.
Evolent Health (EVH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Evolent Health (EVH) Reports Q2 Loss, Misses Revenue Estimates
Evolent Health (EVH) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of $0.09. This compares to earnings of $0.3 per share a year ago.
Earnings Preview: Evolent Health (EVH) Q2 Earnings Expected to Decline
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
